Success Metrics

Clinical Success Rate

88.9%

Based on 8 completed trials

Completion Rate

89%(8/9)

Active Trials

0(0%)

Results Posted

25%(2 trials)

Terminated

1(10%)

Phase Distribution

Ph phase_1

20%

Ph phase_2

70%

Ph phase_3

10%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution10 total trials

Phase 1Safety & dosage

2(20.0%)

Phase 2Efficacy & side effects

7(70.0%)

Phase 3Large-scale testing

1(10.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

88.9%

8 of 9 finished

Non-Completion Rate

11.1%

1 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(8)

Terminated(1)

Other(1)

Detailed Status

Completed8

unknown1

Terminated1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

88.9%

Most Advanced

Phase 3

Trials by Phase

Phase 12 (20.0%)

Phase 27 (70.0%)

Phase 31 (10.0%)

Trials by Status

completed880%

unknown110%

terminated110%

Recent Activity

0 active trials

Showing 5 of 10

completedphase_2

Fexinidazole in Human African Trypanosomiasis Due to T. b. Rhodesiense

NCT03974178

completedphase_3

Fexinidazole in Human African Trypanosomiasis Due to T.b. Gambiense at Any Stage

NCT03025789

completedphase_2

Oral Fexinidazole Dosing Regimens for the Treatment of Adults With Chronic Indeterminate Chagas Disease

NCT03587766

completedphase_2

Efficacy and Safety of Fexinidazole in Patients With Stage 1 or Early Stage 2 Human African Trypanosomiasis (HAT) Due to T.b. Gambiense: a Prospective, Multicentre, Open-label Cohort Study, plug-in to the Pivotal Study

NCT02169557

completedphase_2

Efficacy and Safety of Fexinidazole in Children at Least 6 Years Old and Weighing Over 20 kg With Human African Trypanosomiasis (HAT) Due to T.b. Gambiense: a Prospective, Multicentre, Open Study, plug-in to the Pivotal Study

NCT02184689

View all 10 trials

Clinical Trials (10)

Showing 10 of 10 trials

NCT03974178Phase 2

Fexinidazole in Human African Trypanosomiasis Due to T. b. Rhodesiense

Completed

NCT03025789Phase 3

Fexinidazole in Human African Trypanosomiasis Due to T.b. Gambiense at Any Stage

Completed

NCT03587766Phase 2

Oral Fexinidazole Dosing Regimens for the Treatment of Adults With Chronic Indeterminate Chagas Disease

Completed

NCT02169557Phase 2

Efficacy and Safety of Fexinidazole in Patients With Stage 1 or Early Stage 2 Human African Trypanosomiasis (HAT) Due to T.b. Gambiense: a Prospective, Multicentre, Open-label Cohort Study, plug-in to the Pivotal Study

Completed

NCT02184689Phase 2

Efficacy and Safety of Fexinidazole in Children at Least 6 Years Old and Weighing Over 20 kg With Human African Trypanosomiasis (HAT) Due to T.b. Gambiense: a Prospective, Multicentre, Open Study, plug-in to the Pivotal Study

Completed

NCT01685827Phase 2

Pivotal Study of Fexinidazole for Human African Trypanosomiasis in Stage 2

Completed

NCT01340157Phase 1

Fexinidazole (1200mg) Bioavailability Under Different Food Intake Conditions

Completed

NCT01980199Phase 2

Trial to Determine Efficacy of Fexinidazole in Visceral Leihmaniasis Patients in Sudan

Terminated

NCT02571062Phase 1

Bioequivalence Study - Reference Clinical Fexinidazole Tablet Versus Proposed Market Formulation